SAN FRANCISCO, June 12, 2014 – Invitae Corporation, a genetic information company, today announced that it now offers multi-gene testing for hereditary pancreatic cancer, providing clinicians with a reliable, fast and affordable option for their cancer patients and their families. With results typically available within three weeks, this panel includes an analysis of 17 genes and currently is the most comprehensive panel available. The test is available globally and at a contracted price of $1,500 in the United States.
The new Invitae Hereditary Pancreatic Cancer Panel covers the genetic associations most commonly linked to an increased risk of pancreatic cancer and includes the following genes: APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, FANCC, MEN1, MLH1, MSH2, MSH6, PALB2, PALLD, PMS2, STK11, TP53 and VHL. In addition, Invitae offers hereditary pancreatitis genes CFTR and SPINK1, which some providers choose when assessing a patient for hereditary pancreatic cancer. These genes can be included in an Invitae requisition at no additional charge.
Additional hereditary cancer panels are available, including testing for BRCA1 and BRCA2, Lynch Syndrome and other colon cancers, and a 29-gene hereditary cancer syndromes panel.
In addition to covering more genes than tests available from other providers, Invitae’s newest cancer panel provides clinicians and patients with answers more rapidly, at a lower cost.
“Genetic testing for inherited pancreatic cancer is particularly important as most patients are diagnosed at an advanced stage,” said Tuya Pal, MD, Clinical Geneticist, Moffitt Cancer Center. “Given that there are multiple genes that may predispose to inherited pancreatic cancer, multi-gene tests may help us to refine medical management and treatment decisions in affected patients and identify at-risk family members who may benefit from targeted cancer screening and prevention options.”
According to the American Cancer Society, approximately 46,420 people in the United States will be diagnosed with pancreatic cancer, and an estimated 39,590 people will die of pancreatic cancer in 2014.
“Invitae’s new pancreatic cancer panel delivers greater genetic information and thus provides healthcare providers with an important tool to help address the clinical challenges of detecting hereditary pancreatic cancer and managing treatment decisions,” said Invitae’s Federico Monzon, MD. “The release of this new panel enables us to help address a new group of patients who may be at risk for pancreatic cancer with a test that is not only reliable, but affordable and provides rapid results.”
About Invitae Corporation
Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time and a lower price than most single-gene diagnostic tests today. Invitae has raised $87 million from investors, including Thomas McNerney Partners, Casdin Capital, Genesys Capital, Genomic Health, Inc. (NASDAQ: GHDX) and Redmile Group.
For further information, please visit www.invitae.com.